Franchises et coassurance : Questions médicales fréquentes
Nom anglais: Deductibles and Coinsurance
Descriptor UI:D003669
Tree Number:N03.219.521.576.090.300
Termes MeSH sélectionnés :
Fluorodeoxyglucose F18
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Franchises et coassurance : Questions médicales les plus fréquentes",
"headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Participation aux coûts",
"url": "https://questionsmedicales.fr/mesh/D017047",
"about": {
"@type": "MedicalCondition",
"name": "Participation aux coûts",
"code": {
"@type": "MedicalCode",
"code": "D017047",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.219.521.576.090"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance",
"alternateName": "Deductibles and Coinsurance",
"code": {
"@type": "MedicalCode",
"code": "D003669",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "J Frank Wharam",
"url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam",
"affiliation": {
"@type": "Organization",
"name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Alisa B Busch",
"url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch",
"affiliation": {
"@type": "Organization",
"name": "Department of Health Care Policy, Harvard Medical School."
}
},
{
"@type": "Person",
"name": "Fang Zhang",
"url": "https://questionsmedicales.fr/author/Fang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dennis Ross-Degnan",
"url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Mark K Meiselbach",
"url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach",
"affiliation": {
"@type": "Organization",
"name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "18 F-fluorodeoxyglucose PET/computed tomography metabolic parameters and sarcopenia in pancreatic cancer.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37334539",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MNM.0000000000001713"
}
},
{
"@type": "ScholarlyArticle",
"name": "18-Fluoride fluorodeoxyglucose positron emission tomography is impactful in newly diagnosed pancreatic adenocarcinoma.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36582048",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ans.18236"
}
},
{
"@type": "ScholarlyArticle",
"name": "Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.",
"datePublished": "2022-10-05",
"url": "https://questionsmedicales.fr/article/36275809",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fmed.2022.945602"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential Response of Pelvic Bone Marrow Fluorodeoxyglucose Uptake in Patients Receiving Concurrent Chemoradiotherapy.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37339923",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clon.2023.06.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "18F-fluorodeoxyglucose positron emission tomography for the assessment of endo-bronchial involvement in granulomatosis with polyangiitis.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36762747",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/szc6ma"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Économie",
"item": "https://questionsmedicales.fr/mesh/D004467"
},
{
"@type": "ListItem",
"position": 4,
"name": "Financement organisé",
"item": "https://questionsmedicales.fr/mesh/D005381"
},
{
"@type": "ListItem",
"position": 5,
"name": "Assurance",
"item": "https://questionsmedicales.fr/mesh/D007341"
},
{
"@type": "ListItem",
"position": 6,
"name": "Participation aux coûts",
"item": "https://questionsmedicales.fr/mesh/D017047"
},
{
"@type": "ListItem",
"position": 7,
"name": "Franchises et coassurance",
"item": "https://questionsmedicales.fr/mesh/D003669"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Franchises et coassurance - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Franchises et coassurance",
"description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Franchises et coassurance",
"description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Franchises et coassurance",
"description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Franchises et coassurance",
"description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Franchises et coassurance",
"description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Franchises et coassurance",
"description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Fluorodeoxyglucose+F18&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Qu'est-ce qu'une franchise en assurance santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la coassurance ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre franchise et coassurance ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais."
}
},
{
"@type": "Question",
"name": "Comment sont calculées les franchises ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans."
}
},
{
"@type": "Question",
"name": "Les franchises sont-elles remboursables ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les montants de franchise ne sont pas remboursés par l'assurance."
}
},
{
"@type": "Question",
"name": "Quels sont les impacts d'une franchise élevée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment la coassurance affecte-t-elle les patients ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils du stress à cause des franchises ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients."
}
},
{
"@type": "Question",
"name": "Les franchises influencent-elles la santé des patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes financiers liés à la coassurance ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières."
}
},
{
"@type": "Question",
"name": "Comment éviter des frais élevés de franchise ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles."
}
},
{
"@type": "Question",
"name": "Les bilans de santé sont-ils couverts sans franchise ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les franchises ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles."
}
},
{
"@type": "Question",
"name": "Les programmes de prévention réduisent-ils les coûts ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux."
}
},
{
"@type": "Question",
"name": "Comment les patients peuvent-ils planifier leurs soins ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance."
}
},
{
"@type": "Question",
"name": "Comment choisir un plan avec franchise ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils couverts ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan."
}
},
{
"@type": "Question",
"name": "Comment réduire les coûts de coassurance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils soumis à la franchise ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance."
}
},
{
"@type": "Question",
"name": "Les soins d'urgence sont-ils affectés par la coassurance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des franchises élevées ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé."
}
},
{
"@type": "Question",
"name": "La coassurance peut-elle entraîner des complications financières ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes."
}
},
{
"@type": "Question",
"name": "Les patients évitent-ils des soins à cause des coûts ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment les complications de santé affectent-elles les coûts ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus."
}
},
{
"@type": "Question",
"name": "Les complications dues à la coassurance sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent les coûts de franchise ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts."
}
},
{
"@type": "Question",
"name": "Comment le choix de l'assurance affecte-t-il les coûts ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles les frais ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés."
}
},
{
"@type": "Question",
"name": "Les jeunes adultes ont-ils des franchises plus basses ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses."
}
},
{
"@type": "Question",
"name": "Les habitudes de santé influencent-elles les coûts ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme."
}
}
]
}
]
}
This study aimed to investigate the association between 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) and clinicopathological characteristics and sarcopenia in patients with pancrea...
Clinicopathological factors and 18 F-FDG PET/CT metabolic parameters of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of the primary tumor (SUVmax_P, MTV_P, and TL...
Among 113 patients, 49 patients (43.4%) were diagnosed with sarcopenia. Compared with nonsarcopenia, sarcopenia more frequently occurred in the older population ( P = 0.027), males ( P = 0.014), and l...
Sarcopenia increased with declining SUVmax_M in pancreatic cancer. Compared with SMI, SUVmax_M offers a more straightforward prediction of sarcopenia, thus a promising measurement to be incorporated i...
Adenocarcinoma of the pancreas has a dismal prognosis. Surgical resection increases survival but is reliant on accurate detection and staging of disease. In overseas studies,...
We analysed the PET findings of these cancers (presence and degree of metabolic activity in the primary lesion, as well as within malignant nodal and metastatic lesions) and compared the pre- and post...
Of 51 patients we found that (a) increasing SUV...
In newly diagnosed pancreatic adenocarcinoma, parameters in PET correlate with disease stage and the overall findings contribute to a significant management change in about 35% of patients....
Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung c...
Irradiation of pelvic bone marrow (PBM) at the level of the typical low dose bath of intensity-modulated radiotherapy delivery (10-20 Gy) is associated with an increased risk of haematological toxicit...
Active and inactive PBM were contoured on baseline PET-CT and using deformable registration mapped onto mid-treatment PET-CT. Volumes were cropped to exclude definitive bone, voxel SUV extracted and t...
Active and inactive PBM were shown to respond differentially to concurrent chemoradiotherapy. The median absolute response of active PBM for all patients was -0.25 g/ml, whereas the median inactive PB...
These results would support the definition of active PBM as FDG uptake greater than the mean of the whole structure as being representative of underlying cell physiology. This work would support the d...
Bronchial stenosis is an uncommon but potentially life-threatening complication of granulomatosis with polyangiitis (GPA). The development of lower respiratory tract stenoses in patients with GPA is t...
Biology-guided radiotherapy (BgRT) is a novel radiation delivery approach utilizing fluorodeoxyglucose (FDG) activity on positron emission tomography (PET) imaging performed in real-time to track and ...
We reviewed the charts of 50 lung adenocarcinoma patients with liver metastases. The following variables were collected: SUVmax and SUVmean for each liver metastasis, SUVmean and SUVmax at 5 and 10 mm...
82 measurable liver metastases were included in the final analysis. The average SUVbackground of liver was 2.26 (95% confidence interval [CI] 2.17-2.35); average SUVmean for liver metastases was 5.31 ...
This is the first study to comprehensively characterize FDG contrast between the liver tumor and background, referred to as NSUV. Due to the high background SUV normally found in the liver, this work ...
To evaluate whether a machine learning classifier can evaluate image quality of maximum intensity projection (MIP) images from F18-FDG-PET scans. A total of 400 MIP images from F18-FDG-PET with simula...
18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a diagnostic tool widely used in adult oncology and some pediatric oncological settings. There are no est...
We retrospectively reviewed patients with mGCT treated in Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) centers who underwent 18F-FDG PET/CT between 2011 and 2021....
Seventeen patients (median age 13 y) were included in the study. In 14 patients, 18F-FDG PET/CT was performed at diagnosis; 12 showed pathologic uptake. The 2 18F-FDG PET/CT negative cases were histol...
In our review of a series of children with mGCT, 18F-FDG PET/CT after neoadjuvant chemotherapy showed 1 of 5 false negatives and was unable to discriminate between residual malignant component and mat...
Brain metastases may manifest as hypermetabolism or hypometabolism compared with normal brain activity on 18 fluorine-fluorodeoxyglucose PET ( 18 F-FDG PET). We aim to undertake a systematic review an...
PubMed and EMBASE were searched systematically. Study selection and quality assessment were performed independently by two authors. Meta-analysis was performed using a bivariate random-effects model. ...
A total of 2227 patients from 11 studies were included in the review and analysis. Using the bivariate random-effects model, summary patient-based sensitivity and specificity for all 11 studies were e...
Our systematic review and meta-analysis showed that FDG PET has overall limited sensitivity and excellent specificity in the detection of brain metastases from extracranial primary cancers. Importantl...
Response of pyogenic spine infection to antibiotic therapy is usually based on nonspecific symptoms and inflammation markers. Abnormalities on MRI persist too long to influence therapy. Is FDG-PET/CT ...
Retrospective study. Sequential FDG-PET/CTs done to assess treatment response over a 4-year period. Recurrence of infection after stopping treatment was the endpoint....
One hundred seven patients enrolled. First treatment response scan showed no signs of infection in 69 patients (low risk). Twenty-four additional patients underwent additional treatment after an initi...
Risk stratification proposed: A low-risk scan with only inflammation at a destroyed joint indicates negligible risk of recurrence. Unexplained activity in bone, soft tissue or spinal canal indicates h...